1. Home
  2. MRKR vs ASBP Comparison

MRKR vs ASBP Comparison

Compare MRKR & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • ASBP
  • Stock Information
  • Founded
  • MRKR N/A
  • ASBP 2021
  • Country
  • MRKR United States
  • ASBP United States
  • Employees
  • MRKR N/A
  • ASBP N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • ASBP Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRKR Health Care
  • ASBP Health Care
  • Exchange
  • MRKR Nasdaq
  • ASBP Nasdaq
  • Market Cap
  • MRKR 13.4M
  • ASBP 11.9M
  • IPO Year
  • MRKR N/A
  • ASBP N/A
  • Fundamental
  • Price
  • MRKR $1.77
  • ASBP $0.38
  • Analyst Decision
  • MRKR Strong Buy
  • ASBP
  • Analyst Count
  • MRKR 3
  • ASBP 0
  • Target Price
  • MRKR $13.17
  • ASBP N/A
  • AVG Volume (30 Days)
  • MRKR 185.7K
  • ASBP 36.0M
  • Earning Date
  • MRKR 05-15-2025
  • ASBP 05-14-2025
  • Dividend Yield
  • MRKR N/A
  • ASBP N/A
  • EPS Growth
  • MRKR N/A
  • ASBP N/A
  • EPS
  • MRKR N/A
  • ASBP N/A
  • Revenue
  • MRKR $5,696,123.00
  • ASBP N/A
  • Revenue This Year
  • MRKR N/A
  • ASBP N/A
  • Revenue Next Year
  • MRKR $11.28
  • ASBP N/A
  • P/E Ratio
  • MRKR N/A
  • ASBP N/A
  • Revenue Growth
  • MRKR 71.53
  • ASBP N/A
  • 52 Week Low
  • MRKR $0.95
  • ASBP $0.22
  • 52 Week High
  • MRKR $5.99
  • ASBP $15.80
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 72.77
  • ASBP N/A
  • Support Level
  • MRKR $1.12
  • ASBP N/A
  • Resistance Level
  • MRKR $1.82
  • ASBP N/A
  • Average True Range (ATR)
  • MRKR 0.17
  • ASBP 0.00
  • MACD
  • MRKR 0.06
  • ASBP 0.00
  • Stochastic Oscillator
  • MRKR 93.33
  • ASBP 0.00

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

About ASBP Aspire Biopharma Holdings Inc. Common Stock

Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.

Share on Social Networks: